Drug Trial Radar · NCT05557591
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Actual
Start
Apr 21, 2023
Primary completion
Jan 26, 2028
Study completion May 16, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Sep 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the drug less effective or could lead to side effects)
Conditions
- Advanced Non-Small Cell Lung Cancer
Interventions
BNT116Drug
BNT116 is administered by IV injection.
CemiplimabDrug
Cemiplimab is administered Q3W by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) as assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Time frame: Up to 136 weeks from randomization
Locations
52 sites in 7 countries. Site status is shown where the registry gives one.
The Oncology Institute of Hope and Innovation
Los Angeles, California
UCLA Medical Center
Santa Monica, California
Norton Cancer Institute, Downtown
Louisville, Kentucky
San Juan Oncology Associates
Farmington, New Mexico
Weill Cornell Medicine
New York, New York
FirstHealth of the Carolinas Outpatient Cancer Center
Pinehurst, North Carolina
Millenium Research & Clinical Development
Houston, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Northwest Medical Specialties, PLLC
Tacoma, Washington
LTD High Technology Hospital Medcenter
Batumi, Georgia
LLC Todua Clinic
Tbilisi, Georgia
LTD New Hospitals
Tbilisi, Georgia
LTD Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
Tbilisi, Georgia
LTD Cancer Research Centre
Tbilisi, Georgia
Caucasus Medical Centre
Tbilisi, Georgia
Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt
Frankfurt, Germany
Universitaetsklinikum Giessen Und Marburg Gmbh Standort Giessen
Giessen, Germany
Krankenhaus Martha-Maria Halle-Doelau gGmbH
Halle, Germany
Klinikverbund Kempten-Oberallgäu
Kempten, Germany
Staedtisches Klinikum Muenchen Bogenhausen
München, Bavaria, Germany
National Cancer Center Korea
Goyang, South Korea
Asan Medical Center
Seoul, South Korea
Yonsei Severance
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Korea University Anam Hospital
Seoul, Gyeonggi-do, South Korea
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
Hospital General Universitario Gregorio Marañon (HGUGM)
Madrid, Spain
Clinica Universidad de Navarra - Madrid
Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Hospital Regional Universitario de Malaga
Málaga, Spain
Hospital Universitario Virgen del Rocio
Málaga, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Instituto Valenciano de Oncologia
Valencia, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Catalan Institute of Oncology Badalona
Badalona, Barcelona, Spain
Althaia Xarxa Assistencial Universitaria Manresa
Manresa, Barcelona, Spain
Consorcio Hospitalario Provincial de Castellon
Castellon, Castellon, Spain
Kaohsiung Medical University - Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Taipei Tzu Chi Hospital
New Taipei City, Taiwan
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.